Izumi Kouji, Shigehara Kazuyoshi, Nohara Takahiro, Narimoto Kazutaka, Kadono Yoshifumi, Mizokami Atsushi
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Anticancer Res. 2017 Oct;37(10):5559-5564. doi: 10.21873/anticanres.11988.
BACKGROUND/AIM: Androgen-androgen receptor (AR) signal is known as a powerful driver of prostate cancer progression. We previously reported the limitation of prostate-specific antigen (PSA) at diagnosis as a prognostic biomarker of prostate cancer. Although serum total testosterone (TT) level has been reported as a prognostic biomarker for prostate cancer, its usability is still controversial. We examined the potential and characteristics of TT as a biomarker.
Serum TT levels of patients who underwent prostate biopsy were measured, and prostate cancer-specific survival (PCaSS), overall survival (OS), and the correlation between staging and serum TT level were analyzed.
Of 379 biopsied patients, 255 were diagnosed with prostate cancer. The patients were divided into five groups according to their serum TT levels; patients with serum TT levels of <2 or ≥8 ng/ml (ENDs) had worse PCaSS and OS compared with those with middle serum TT levels between 2 and 8 ng/ml (MIDs). Moreover, ENDs showed a tendency of having castration-resistant cancer with advanced stage (T4 or N1 or M1). The TNM stage in ENDs was significantly higher than in MIDs.
Although low serum TT level has been reported to indicate worse outcome in patients with prostate cancer, this study showed that both low as well as high serum TT levels indicate poor prognosis.
背景/目的：雄激素-雄激素受体（AR）信号是前列腺癌进展的强大驱动因素。我们之前报道了前列腺特异性抗原（PSA）在前列腺癌诊断时作为预后生物标志物的局限性。尽管血清总睾酮（TT）水平已被报道为前列腺癌的预后生物标志物，但其可用性仍存在争议。我们研究了TT作为生物标志物的潜力和特征。
测量接受前列腺活检患者的血清TT水平，并分析前列腺癌特异性生存（PCaSS）、总生存（OS）以及分期与血清TT水平之间的相关性。
在379例接受活检的患者中，255例被诊断为前列腺癌。根据血清TT水平将患者分为五组；血清TT水平<2或≥8 ng/ml的患者（极端值组）与血清TT水平在2至8 ng/ml之间的患者（中间值组）相比，PCaSS和OS更差。此外，极端值组显示出晚期（T4或N1或M1）去势抵抗性癌症的趋势。极端值组的TNM分期显著高于中间值组。
尽管已有报道称血清TT水平低表明前列腺癌患者预后较差，但本研究表明血清TT水平低和高均表明预后不良。
